The short answer is it depends on several variables most importantly, whether the patient has been experiencing recurrent infections. Additionally, the presence or absence of coincidental lymphocytopenia can be relevant. Worth mentioning that the most common hematologic manifestations in lupus are a...

Tagging on to Dr. @H Michael Belmont's excellent answer and DDX, after those things are ruled out, I would not escalate therapy in the absence of recurrent infections (you would be treating yourself rather than treating the patient). Glucocorticosteroids would certainly increase the counts but at th...

For isolated neutropenia associated with SLE, I will not change therapies. The exception would be if the patient is actually having severe and/or frequent infections in which case a more thorough evaluation for the precise cause (marrow suppression, autoantibody mediated) will be warranted.

Many important issues have already been discussed and I will try to add to those without repeating. I have had 2 patients like this. Neither of them had “purely isolated” leukopenia/neutropenia: both had positive anti-neutrophil antibodies.  So my response is that it all depends o...

@Emilio Gonzalez: You bring up a great point about biologics. Anifrolumab did show that it improved neutropenia and lymphopenia in the phase-II clinical trial (MUSE) in a report by Casey et al., PMID 30538817.

I am very careful about the use of biologics in patients with leucopenia. As far as I know, belimumab did not show an improvement in the hematologic domain in the pivotal clinical trials.